Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purple wheat is a specialized variety of whole-grain wheat, specifically the **CDC Primepurple** cultivar, characterized by high concentrations of anthocyanin pigments in the bran layer. Developed by the Crop Development Centre (CDC) and commercially distributed as **AnthoGrain** by InfraReady Products Ltd, it is studied for its potential health benefits in managing chronic inflammation and metabolic disorders. Clinical research indicates that consumption of purple wheat products, such as bran-enriched convenience bars, can modestly improve metabolic markers including interleukin-6 (IL-6) and fasting glucose levels in overweight and obese adults with elevated high-sensitivity C-reactive protein (hs-CRP). Its mechanism of action is attributed to its high content of dietary fiber and bioactive phytochemicals, particularly anthocyanins and phenolic acids like ferulic acid, which exhibit antioxidant and anti-inflammatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on purple wheat.